Latest filings (excl ownership)
8-K
Merck Announces First-Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
10-K/A
2023 FY
Annual report (amended)
11 Apr 24
PX14A6G
Letter to shareholders
1 Apr 24
PX14A6G
Letter to shareholders
27 Mar 24
S-3ASR
Automatic shelf registration
19 Mar 24
S-3ASR
Automatic shelf registration
19 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
1 Feb 24
8-K
Departure of Directors or Certain Officers
28 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Merck Announces Third-Quarter 2023 Financial Results
26 Oct 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Merck Announces Second-Quarter 2023 Financial Results
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
SD
Conflict minerals disclosure
22 May 23
PX14A6G
Letter to shareholders
18 May 23
8-K
Other Events
17 May 23
424B5
Prospectus supplement for primary offering
10 May 23
FWP
Free writing prospectus
8 May 23
424B5
Prospectus supplement for primary offering
8 May 23
10-Q
2023 Q1
Quarterly report
5 May 23
8-K
Merck Announces First-Quarter 2023 Financial Results
27 Apr 23
PX14A6G
Letter to shareholders
21 Apr 23
PX14A6G
Letter to shareholders
19 Apr 23
PX14A6G
Letter to shareholders
12 Apr 23
ARS
2022 FY
Annual report to shareholders
3 Apr 23
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEF 14A
Definitive proxy
3 Apr 23
10-K
2022 FY
Annual report
24 Feb 23
8-K
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
2 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Merck Announces Third-Quarter 2022 Financial Results
27 Oct 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Merck Announces Second-Quarter 2022 Financial Results
28 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
26 May 22
SD
Conflict minerals disclosure
20 May 22
Latest ownership filings
3
Betty D Larson
8 Apr 24
4
PETER C WENDELL
29 Mar 24
4
Christine E Seidman
29 Mar 24
4
THOMAS H GLOCER
29 Mar 24
4
Mary Ellen Coe
29 Mar 24
4
Harpoon Therapeutics, Inc.
11 Mar 24
4
Caroline Litchfield
15 Feb 24
4
Robert M Davis
15 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
4
Joseph Romanelli
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
4
Dean Y Li
12 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
4
David Michael Williams
8 Feb 24
144
Notice of proposed sale of securities
7 Feb 24
4
Johannes Jacobus Oosthuizen
5 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
4
STEVEN MIZELL
2 Feb 24
4
Jennifer Zachary
2 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Johannes Jacobus Oosthuizen
24 Jan 24
4
Dalton Smart
24 Jan 24
4
David Michael Williams
24 Jan 24
4
STEVEN MIZELL
24 Jan 24
4
Jennifer Zachary
24 Jan 24
4
Dean Y Li
24 Jan 24
4
Robert M Davis
24 Jan 24
4
Richard R. DeLuca
24 Jan 24
4
Sanat Chattopadhyay
24 Jan 24
4
Caroline Litchfield
24 Jan 24
4
Michael A Klobuchar
24 Jan 24
SC 13G
Evaxion Biotech A/S
23 Jan 24
3
Harpoon Therapeutics, Inc.
17 Jan 24
4
PETER C WENDELL
2 Jan 24